- The stock price of Lantern Pharma Inc. (NASDAQ: LTRN) increased by over 10% pre-market. This is why it happened.
The stock price of Lantern Pharma Inc. (NASDAQ: LTRN) – a clinical-stage biopharmaceutical company using its proprietary RADR artificial intelligence (AI) platform to transform the cost, pace, and timeline of oncology drug discovery and development – increased by over 10% pre-market. Investors are responding positively to Lantern Pharma announcing positive new data from its ongoing pancreatic cancer collaboration with the Pancreatic Cancer Institute at Fox Chase Cancer Center. And the preclinical data demonstrated that the drug candidate LP-184 demonstrated significant and rapid pancreatic tumor shrinkage, by over 90%, in in-vivo mouse models in 8 weeks. As a comparison, the tumors in the untreated mice grew by over eleven-fold in volume during the same 8 week period.
The additional positive data on the efficacy and potency of LP-184 was gathered from 6 pancreatic cancer cell lines and an additional 5 patient-derived xenograft (PDX) ex-vivo tumor models. And the significant reduction of cancer cells and cancer cell growth was observed across all pancreatic cancer cell lines and PDX models that were tested in the study with IC50 values being in the nanomolar range (45-270 nM). The data and observations are being prepared for peer-reviewed publications, manuscripts, and scientific conferences. And data from this study will be used to power future insights and analysis provided by Lantern’s A.I. platform RADR in addition to further enhancing the signature of response for LP-184 in pancreatic cancers. Lantern believes this to be a significant positive advancement for LP-184 in targeted pancreatic cancers and they are planning to advance the collaboration with Fox Chase Cancer Center into the next phase.
CRISPR knockout data had confirmed the importance of PTGR1 in LP-184 cytotoxicity in pancreatic cancer and validates the RADR-generated hypothesis that PTGR1 plays the leading role in orchestrating responsiveness of tumors to LP-184. And the research conducted at Fox Chase Cancer Center leveraged CRISPR editing to silence the gene PTGR1 in pancreatic cancer cells. This resulted in virtually no response by the pancreatic cancer cells to the drug. Those pancreatic cancer cells with PTGR1 expression (untouched by gene-editing) had heightened the response to LP-184 causing cell death and IC50 values in the sub-100nM range. And Lantern believes that using a defined genetic signature for patient selection can enhance the likelihood of clinical trial success and focus future clinical trials on those patients that will benefit most from the therapy.
The research was conducted in collaboration with Dr. Igor Astsaturov, an established, NCI-funded, physician-scientist and co-leader of the Marvin & Conchetta Greenberg Pancreatic Cancer Institute at Fox Chase Cancer Center. And the results demonstrated that LP-184 significantly and rapidly shrunk pancreatic cancer xenografts in mice, and after treatment with once-weekly dosing at 3 mg/kg for 8 weeks, no tumors were present in 1 of 4 treated mice, and in 3 of 4 mice the average size of remaining tumors was approximately 7% of the original tumor and 146-fold smaller than the untreated tumors.
The additional research was conducted with Dr. Astsaturov to further confirm the increased sensitivity to LP-184 in tumors that had damage to DNA repair pathways. And it was observed that pancreatic tumors that harbored genetic alternations in the following DNA repair pathways — NER (nucleotide excision repair) and HR (homologous recombination) — had 2-fold increased sensitivity to LP-184. This observed data showed implications in increasing the potential number of pancreatic cancer patients that can benefit from LP-184 and also in confirming prior Lantern research focused on aiming this drug candidate at other cancers that have DNA repair pathway mutations. These could be mutations or deficiencies in genes like BRCA1, BRCA2, ATM, ATR, ERCC2, ERCC3, ERCC4, ERCC5, ERCC6, FANCD2, RAD51, and PALB2.
Pancreatic cancer is an orphan disease and has a 5-year survival rate of 7.9%. And this means that only approximately 8 in 100 people will have survived for five years and beyond. The 10-year survival rate of the disease is 1%, meaning only approximately 1 in 100 people survive 10 years and beyond. And pancreatic cancer has among the lowest 5-year survival rate of any of the 22 common cancers. GLOBOCAN estimates that for pancreatic cancer there are about 490,000 thousand new cases of pancreatic cancer globally with over 62,000 occurring in North America annually. And targeting a specific subset of pancreatic cancer patients that are genetically defined has the potential to increase beneficial therapeutic options for patients and may ultimately improve survival for those with this cancer.
Lantern believes that LP-184 acts by damaging DNA selectively in tumors that express high levels of the enzyme PTGR1 – which happens in several solid tumors. And analysis with Lantern’s data platform RADR indicated that 35-40% of pancreatic cancer transcriptomes in clinical databases have elevated PTGR1 expression. And Lantern has also begun discussions on the design of first-in-human clinical studies for LP-184 in collaboration with Dr. Igor Astsaturov and other key opinion leaders in the pancreatic cancer treatment landscape. Lantern plans on initiating IND (Investigational New Drug) application enabling animal studies later this year, and Phase 1 human trials following the filing of a future IND application.
“These data mechanistically validate LP-184’s potential as a synthetic lethal agent in many HRD (homologous recombination deficient) and NERD (nucleotide excision repair deficient) cancers. As a result, these data may be highly supportive of a future role for LP-184 in a genetically-defined subset of pancreatic cancer.”
— Dr. Astsaturov
“We are highly encouraged by the results of this preclinical research and look forward to reporting the full results at future scientific conferences and in publications. The study observed the significant and targeted anti-tumor effects of LP-184, even in pancreatic cancers that were resistant to standard-of-care drugs. Moreover, we also validated through the elegant work done with Dr. Astsaturov’s lab, by use of CRISPR-editing, that PTGR1 does directly link to the anti-tumor activity of LP-184. We expect that we will be able to exploit this biomarker mechanism in various tumors beyond pancreatic in the future.”
— Dr. Kishor Bhatia, Lantern’s Chief Scientific Officer
Disclaimer: This content is intended for informational purposes. Before making any investment, you should do your own analysis.